Oruka Therapeutics (ORKA) Share-based Compensation (2010 - 2026)

Oruka Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $7.0 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 42.7% year-over-year to $7.0 million; the TTM figure through Mar 2026 stood at $26.3 million (up 33.51% YoY), while the FY2025 annual figure was $24.2 million, up 62.48% from the prior year.
• Share-based Compensation was $7.0 million for Q1 2026 at Oruka Therapeutics, up from $4.1 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $10.2 million in Q3 2025 to a low of $97000.0 in Q3 2022.
• Historically, Share-based Compensation has averaged $2.8 million across 5 years, with a median of $204000.0 in 2023.
• Biggest YoY gain for Share-based Compensation was 5744.81% in 2024; the steepest drop was 50.98% in 2024.
• A 5-year view of Share-based Compensation shows it stood at $120000.0 in 2022, then increased by 17.5% to $141000.0 in 2023, then soared by 3552.48% to $5.1 million in 2024, then declined by 20.1% to $4.1 million in 2025, then surged by 69.33% to $7.0 million in 2026.
• The last three Share-based Compensation figures came in at $7.0 million (Q1 2026), $4.1 million (Q4 2025), and $10.2 million (Q3 2025), per Business Quant data.